Genomatix Software GmbH (Munich) announced today that Sanofi-Aventis has renewed its licenses for Multi-Site access to the Genomatix Microarray Analysis Pipeline.
The pipeline provides a fully integrated, user friendly solution for the analysis of expression and tiling microarray experiments, including the powerful ChIP on chip studies. Genomatix software module ChipInspector seamlessly integrates with additional modules (BiblioSphere PathwayEdition, ElDorado, Gene2Promoter, and GEMS Launcher) to achieve a molecular level understanding of how genes are regulated and co-regulated, providing the scientists at Sanofi-Aventis a comprehensive gene network and pathway analysis.
Martin Seifert, Vice President Microarray Business and Collaborative Research at Genomatix stated: “We are pleased that our existing relationship with Sanofi-Aventis has led to an extension of their existing licensing agreement. It confirms the validity of our integrated approach to understanding gene regulation by combining state of the art software, biological data bases, expert systems and scientific support, to provide a complete solution for the computational biologist.”
Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, ChIP on chip, regulatory network and pathway mining, and promoter analysis on sequence level. Genomatix has published more than 170 peer reviewed scientific papers that have been cited in more than 4,000 papers. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.